Moffitt researchers develop tool to estimate genetic diversity and ancestry of cell lines
New article in Cancer Research shows cancer cell lines lack genetic diversity
TAMPA, Fla. – Cancer is a highly varied disease, with genetic differences among different tumor types, individuals and ancestral populations. These genetic differences can impact disease aggressiveness, the type of disease, and the response to therapy. It is important that scientists have proper tools and model systems to study how these variations affect cancer development and devise effective therapies for patients of all genetic backgrounds. In a new paper published in Cancer Research, Moffitt Cancer Center researchers, in collaboration with scientists at Ponce Health Sciences University in Puerto Rico, investigated this issue by creating an online tool that can be used by scientists to determine the genetic ancestral origin of more than 1300 different cell lines.
In cancer research, cell lines established from patient tumors are used in laboratory experiments as model systems to understand the molecular and cellular basis of cancer, identify therapeutic targets and develop novel treatments. However, the genetic ancestry of these cell lines is often unknown or incomplete. As a result, scientific data may not accurately reflect the diverse populations that exist throughout the world, resulting in less effective patient management and treatments for different populations.
The research team performed an extensive set of analyses to improve on this knowledge gap by examining the genetic ancestry of 1,393 cancer cell lines based on known populations. They found that these commonly used cell lines do not represent the diverse ancestry of the human population. The majority, 62.46 percent, of the cell lines were determined to be from European origin, while 29.18 percent were from East Asian origin. All other populations were represented by less than 10 percent of the analyzed cell lines, including 5.26 percent of African origin, 0.86 percent of African American origin and 1.95 percent of Hispanic/Latino origin. Additionally, many ancestral populations were largely absent or underrepresented in cell lines for specific cancer types. For example, African American men are known to be diagnosed with prostate cancer at a younger age and have a higher risk of dying from the disease than other populations. However, only 1 out of 10 prostate cancer cell lines was found to represent African ancestral genetic factors.
With the information they obtained, the team created an online, interactive web-based tool that allows researchers to determine the genetic ancestry of cell lines. “This information can be used by scientists as a data and visualization tool to show the genetic ancestry of the cell lines they are using for experiments,” said Steven Eschrich, PhD, lead author of the article and senior member of the Biostatistics and Bioinformatics Department at Moffitt. “We believe that this new tool, representing diverse ancestries, will be an important resource to reduce the knowledge gaps that exist about disease prevention and treatment among diverse ancestral populations.”
“We expect this resource to allow researchers access to ancestry in cell line models and to contribute to efforts to address the underrepresentation in cancer types with clear disparities. Incorporating estimated genetic ancestry within cell line molecular biology and drug discovery studies can significantly improve the rigor, reproducibility and relevance of cancer research activities, not just those explicitly examining the role of genetic ancestry in cancer biology,” said Julie Dutil, Ph.D., professor at Ponce Health Sciences University.
The study was funded by the National Cancer Institute through grants supporting the Ponce Health Sciences University-Moffitt Cancer Center Partnership and Moffitt’s Cancer Informatics Shared Resource.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 50 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt devotes more than 2 million square feet to research and patient care. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 6,000 team members, Moffitt has an economic impact in the state of $2.5 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter and YouTube.
Related Journal Article